The first asset, EpiDex®, is an autologous epidermal equivalent that provides a surgery-free approach to healing chronic venous leg ulcers (VLUs). The second asset, now named healiva®002, is an off-the-shelf allogeneic cell therapy.
Lead Product(s): Tissue-engineered Autologous Outer Root Sheath Keratinocytes
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Epidex
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 01, 2022
Notably, a non-randomized, case-controlled, investigator sponsored proof of concept study evaluating AGGRASTAT® in combination with standard of care in patients with severe COVID-19 and hypercoagulability found that enhanced platelet inhibition improves hypoxemia.
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Aggrastat
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2020